KALA - Kala Pharmaceuticals EPS in-line misses on revenue

Kala Pharmaceuticals (NASDAQ:KALA): Q3 GAAP EPS of -$0.43 in-line. Revenue of $3.1M (+39.6% Y/Y) misses by $2.06M. Press Release As of September 30, 2021, Kala had cash and cash equivalents of $124.5M, compared to $149.6M of cash, cash equivalents and short-term investments as of June 30, 2021.  Based on its current plans, including the costs to acquire Combangio and develop KPI-012, Kala anticipates that its cash resources as of September 30, 2021, together with anticipated revenue from EYSUVIS and INVELTYS and certain cost containment measures, will enable it to fund its operations until the second quarter of 2023.

For further details see:

Kala Pharmaceuticals EPS in-line, misses on revenue